Cystic Fibrosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children or adults who have moderate or IgE-mediated asthma (a type of asthma triggered by the immune system's allergic response)
- Children or adults who have cystic fibrosis
- Children or adults who are generally healthy and do not have any lung conditions (participating as a comparison group)
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Petr Dzubak, MD, PhD., The Institute of Molecular and Translational Medicine, Czech Republic
Phone: 585632150
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Biomarker identification using method of High Resolution Mass Spectrometry processed on Orbitrap Velos Elite machine; FEV1 determination in Cystic Fibrosis patients; FVC determination in Cystic Fibrosis patients; Amylase readings in blood serum in Cystic Fibrosis patients; Lipase readings in blood serum in Cystic Fibrosis patients; Microbiology cultivation in Cystic Fibrosis patients; CT in Cystic Fibrosis patients; RTG in Cystic Fibrosis patients
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.